Carbamate as a potential anti‐Alzheimer's pharmacophore: A review
Drug Development Research · 2023-12 · 84 (8) · 1624-1651
DOI: 10.1002/ddr.22113 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 11.09.2023. Verfasst von Yash Pal Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Carbamates, Alzheimer Disease. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 105 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive age‐related neurodegenerative brain disorder, which leads to loss of memory and other cognitive dysfunction. The underlying mechanisms of AD pathogenesis are very complex and still not fully explored. Cholinergic neuronal loss, accumulation of amyloid plaque, metal ions dyshomeostasis, tau hyperphosphorylation, oxidative stress, neuroinflammation, and mitochondrial dysfunction are major hallmarks of AD. The current treatment options for AD are acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and NMDA receptor antagonists (memantine). These FDA‐approved drugs mainly provide symptomatic relief without addressing the pathological aspects of disease progression. So, there is an urgent need for novel drug development that not only addresses the basic mechanisms of the disease but also shows the neuroprotective property. Various research groups across the globe are working on the development of multifunctional agents for AD amelioration using different core scaffolds for their design, and carbamate is among them. Rivastigmine was the first carbamate drug investigated for AD management. The carbamate fragment, a core scaffold of rivastigmine, act as a potential inhibitor of acetylcholinesterase. In this review, we summarize the last 10 years of research conducted on the modification of carbamate with different substituents which primarily target ChE inhibition, reduce oxidative stress, and modulate Aβ aggregation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, India.
- Department of Biological Science, University of Texas, Dallas, Texas, USA.
ORCID-Profile: Yash Pal Singh, Navneet Kumar, Prabha Garg
Zitieren
APA
Singh, Y. P., Kumar, N., Chauhan, B. S., & Garg, P. (2023). Carbamate as a potential anti‐Alzheimer's pharmacophore: A review. Drug Development Research, 84(8), 1624-1651. https://doi.org/10.1002/ddr.22113
Vancouver
Singh YP, Kumar N, Chauhan BS, Garg P. Carbamate as a potential anti‐Alzheimer's pharmacophore: A review. Drug Development Research. 2023;84(8):1624-1651. doi:10.1002/ddr.22113
BibTeX
@article{Singh2023,
author = {Singh, Yash Pal and Kumar, Navneet and Chauhan, Brijesh Singh and Garg, Prabha},
title = {Carbamate as a potential anti‐Alzheimer's pharmacophore: A review},
journal = {Drug Development Research},
year = {2023},
volume = {84},
number = {8},
pages = {1624--1651},
doi = {10.1002/ddr.22113}
}
EUVIMED